Breast Cancer Risk

Oncology
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Precision BioSciences
1 program
Breast Cancer, Cardiometabolic, Cardiovascular Risk Screening and Follow upN/A1 trial
Active Trials
NCT05848856Not Yet Recruiting10,000Est. Sep 2035
Ambry Genetics
Ambry GeneticsCA - Aliso Viejo
1 program
Clinical Implementation of a Polygenic Risk Score (PRS) for Breast CancerN/A1 trial
Active Trials
NCT03688204CompletedEst. Nov 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Precision BioSciencesBreast Cancer, Cardiometabolic, Cardiovascular Risk Screening and Follow up
Ambry GeneticsClinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer

Clinical Trials (2)

Total enrollment: 10,000 patients across 2 trials

NCT05848856Precision BioSciencesBreast Cancer, Cardiometabolic, Cardiovascular Risk Screening and Follow up

The RISC Registry--Risk Informed Screening Registry

Start: Sep 2024Est. completion: Sep 203510,000 patients
N/ANot Yet Recruiting
NCT03688204Ambry GeneticsClinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer

Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer

Start: Sep 2018Est. completion: Nov 2020
N/ACompleted

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space